Tandem Diabetes Takes Aim at Medtronic's Artificial Pancreas - Motley Fool


Motley Fool

Tandem Diabetes Takes Aim at Medtronic's Artificial Pancreas
Motley Fool
Insulin pump maker Tandem Diabetes Care (NASDAQ:TNDM) has secured an FDA OK that puts it on track to challenge Medtronic (NYSE:MDT) for the lead in the emerging market for closed-loop insulin systems. Is Tandem Diabetes stock a buy?

and more Â»


from diabetes - Google News